Even though November’s full moon had come and gone more than a week previous, Werewolf Therapeutics Inc. came out of the shadows Wednesday with a $56 million series A fundraiser to state its plans to develop immune-stimulatory therapeutics to trigger immune responses to cancer.

Paris-based Tissium was first founded in 2013 by professors Robert Langer of MIT and Jeffrey Karp of Brigham and Women’s Hospital as Gecko Biomedical. But now it aims to expand beyond its original focus on surgical sealants and adhesives into barriers, plugs, drug delivery and 3D printed implantable devices. To support that wider focus, the company changed its name and has now raised €38.75 million (US$42.78 million) in a series B financing.